Lunesta Manufacturing, Supply & Shortage History

From Sepracor to Sunovion: The Brand-Name Origin Story

Eszopiclone began as a strategic molecular refinement. Sepracor Inc., a Massachusetts-based company specializing in single-isomer drugs, isolated the (S)-enantiomer of zopiclone, a racemic cyclopyrrolone hypnotic already marketed in Europe and Canada since the 1980s. The rationale was pharmacological: the (S)-enantiomer showed roughly twice the binding affinity at GABA-A receptors compared to the (R)-enantiomer, allowing lower doses with a cleaner side-effect profile [1].

The FDA approved eszopiclone on December 17, 2004, under NDA 021476, making Lunesta the first hypnotic approved for long-term use without a limitation on prescription duration [2]. This was a notable regulatory distinction. Prior sedative-hypnotics carried labeling that restricted use to 7 to 10 days. Sepracor's six-month efficacy trial by Krystal et al. (N=788) demonstrated sustained improvements in sleep latency, wake after sleep onset (WASO), and total sleep time without evidence of tolerance development at 44 weeks, providing the data backbone for this expanded indication [3].

Sepracor rebranded as Sunovion Pharmaceuticals in October 2010, following its acquisition by Dainippon Sumitomo Pharma (now Sumitomo Pharma). Manufacturing of branded Lunesta remained at contract facilities in the United States, with active pharmaceutical ingredient (API) sourced from facilities in India and Europe. Sunovion continued marketing Lunesta until generic competition reshaped the market.

How Eszopiclone Works: Mechanism at the Receptor Level

Eszopiclone is a positive allosteric modulator of the GABA-A receptor, but its binding profile differs from benzodiazepines in a clinically meaningful way. It binds preferentially to GABA-A receptors containing alpha-1, alpha-2, alpha-3, and alpha-5 subunits, with the strongest affinity at alpha-2 and alpha-3 subtypes [4]. This subunit selectivity pattern is associated with sedation and anxiolysis while producing less of the reward-pathway activation linked to abuse potential.

The drug reaches peak plasma concentration in approximately 1 hour. Its elimination half-life averages 6 hours, which is long enough to maintain sleep through the night but short enough to limit next-morning residual sedation at recommended doses [2]. The 2014 FDA labeling revision lowered the recommended starting dose to 1 mg for all patients (previously 2 mg for adults, 1 mg for elderly), reflecting post-marketing data on next-day impairment, particularly in women who metabolize the drug more slowly due to lower CYP3A4 activity [5].

A key distinction from zolpidem: eszopiclone's dual effect on both sleep onset and sleep maintenance. The Krystal 2003 trial showed a mean reduction in subjective sleep-onset latency of 15 minutes and an increase in total sleep time of 45 minutes versus placebo at month 6 [3]. These dual-target effects stem from its broader subunit binding profile compared to zolpidem's alpha-1-selective mechanism.

Patent Expiration and the Generic Flood: 2014 Onward

Lunesta's composition-of-matter patent (U.S. Patent 6,319,926) expired in April 2014. Teva Pharmaceutical Industries filed the first abbreviated new drug application (ANDA) with a Paragraph IV certification, and the FDA approved the first generic eszopiclone in May 2014. Within 18 months, six additional generic manufacturers had received ANDA approvals [6].

The generic entrants included Teva, Lupin Pharmaceuticals, Dr. Reddy's Laboratories, Aurobindo Pharma, Mylan (now Viatris), and Torrent Pharmaceuticals. Each manufactures finished dosage forms at FDA-inspected facilities, though API sourcing concentrates among a smaller number of suppliers. As of 2025, the Drug Master File (DMF) database lists 14 active API manufacturers for eszopiclone, with the majority based in Hyderabad and Mumbai, India [7].

Generic entry collapsed the average wholesale price dramatically. Branded Lunesta carried a wholesale acquisition cost of approximately $11 per tablet in 2013. By 2016, generic eszopiclone averaged $0.45 to $1.20 per tablet depending on strength and manufacturer [8]. This pricing pressure led Sunovion to discontinue active promotion of branded Lunesta in 2016, though the brand NDA remains active and the product is still technically available.

Active Pharmaceutical Ingredient: Synthesis and Sourcing

The synthesis of eszopiclone involves chiral resolution of racemic zopiclone or, more commonly, asymmetric synthesis starting from 6-chloro-2-chloromethyl-imidazo[1,2-a]pyridine. The (S)-enantiomer must meet a chiral purity specification of not less than 99.0% enantiomeric excess (ee) per USP monograph requirements [9].

API manufacturing for eszopiclone is concentrated in India, which produces an estimated 80% of global supply. The major API producers operate FDA-registered facilities in Telangana and Maharashtra states. This geographic concentration creates supply vulnerability. When the FDA issued import alerts or warning letters to Indian pharmaceutical facilities (as occurred during heightened inspection activity in 2018 to 2019), downstream finished-dosage manufacturers faced temporary API shortfalls.

The synthesis involves five to seven chemical steps depending on the route, with the chiral resolution or asymmetric induction step being the yield-limiting stage. Typical overall yields range from 25% to 35%. Raw material inputs include 2-aminopyridine derivatives and chloroacetyl chloride, both commodity chemicals with stable global supply.

FDA Shortage History: A Timeline

Eszopiclone has appeared on the FDA Drug Shortage Database three times since generic entry. Each event was relatively brief compared to shortages affecting other controlled substances.

2016 shortage (July to October): Two generic manufacturers, Lupin and Aurobindo, reported temporary unavailability of the 3 mg strength due to manufacturing delays. The shortage resolved within 14 weeks as Teva and Dr. Reddy's increased production. The root cause was a shared packaging-line constraint at a contract manufacturer in New Jersey [10].

2019 shortage (March to June): This disruption affected all three strengths and was linked to API supply. An FDA warning letter to a major Indian API supplier (issued February 2019) triggered voluntary import holds by two finished-dosage manufacturers. During this period, prescribers reported difficulty filling eszopiclone prescriptions in certain regions, particularly the Southeast and Mountain West [10].

2020 shortage (April to August): The COVID-19 pandemic disrupted pharmaceutical supply chains broadly. Eszopiclone was among approximately 40 controlled substances that experienced temporary supply constraints during Q2 2020. Contributing factors included air freight disruptions from India, increased demand as insomnia rates rose during lockdowns, and staffing reductions at domestic packaging facilities [11]. The American Society of Health-System Pharmacists (ASHP) listed eszopiclone as "currently in shortage" from April 14 through August 3, 2020.

Since August 2020, no new shortage has been formally declared. Current ASHP and FDA databases show eszopiclone as "resolved/no shortage" across all strengths and all manufacturers.

Manufacturing Quality and FDA Inspection Findings

Generic eszopiclone manufacturers must demonstrate bioequivalence to the Lunesta reference listed drug (RLD) under fasting and fed conditions. The FDA's bioequivalence standard requires that the 90% confidence interval for the ratio of generic-to-brand AUC and Cmax falls within 80% to 125% [12].

FDA inspection records from the Office of Pharmaceutical Quality reveal a mixed compliance picture among eszopiclone manufacturers. Between 2015 and 2024, FDA inspectors issued Form 483 observations to three of the seven active finished-dosage manufacturers, citing issues including inadequate cleaning validation on shared equipment lines, insufficient investigation of out-of-specification results for chiral purity, and deficiencies in stability testing protocols [7].

None of these observations escalated to warning letters or product recalls for eszopiclone specifically. The FDA's risk-based inspection model means that facilities manufacturing Schedule IV controlled substances receive inspections approximately every 24 to 30 months, compared to 36 to 48 months for non-controlled generic products.

Dr. Sarah Engel, a pharmacist specializing in drug supply chain analysis at the University of Utah Drug Information Service, has noted: "Eszopiclone's supply chain is actually more resilient than many other generic sedative-hypnotics because of the number of ANDA holders. When one manufacturer drops out temporarily, others can absorb the demand within weeks rather than months."

Current Market Structure and Supply Outlook

As of early 2026, the U.S. eszopiclone market is served by five active finished-dosage manufacturers. IQVIA prescription data from 2024 shows approximately 3.2 million dispensed prescriptions annually, representing a 12% decline from the 2018 peak of 3.64 million prescriptions [8]. This decline reflects broader prescribing trends: the American Academy of Sleep Medicine's 2023 clinical practice guideline conditionally recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, positioning pharmacotherapy including eszopiclone as second-line or adjunctive [13].

The supply-demand balance favors stability. Five manufacturers producing for a slowly declining market means overcapacity exists, which buffers against single-manufacturer disruptions. The key vulnerability remains API concentration. If two or more major API suppliers experienced simultaneous disruptions (regulatory action, geopolitical events, or natural disasters affecting western India), a shortage affecting multiple finished-dosage manufacturers could develop within 60 to 90 days based on typical inventory holding periods.

The Biosecure Act provisions and increased Congressional attention to pharmaceutical supply chain resilience may gradually diversify API sourcing. Several eszopiclone API manufacturers have begun establishing secondary production sites outside India, including facilities in Hungary and China, though these represent less than 15% of current global API volume.

Prescriber Considerations During Supply Disruptions

When eszopiclone becomes temporarily unavailable, clinicians face a substitution decision. The most pharmacologically similar alternative is zopiclone (Imovane), the racemic parent compound, which is approved in Canada and Europe but not in the United States. Within the U.S. formulary, zolpidem extended-release (Ambien CR) offers the closest match for dual sleep-onset and maintenance efficacy, though its alpha-1 selectivity differs mechanistically [14].

The American Academy of Sleep Medicine considers suvorexant (Belsomra), lemborexant (Dayvigo), and low-dose doxepin (Silenor) as reasonable alternatives for sleep maintenance insomnia, each with distinct mechanisms: orexin receptor antagonism for the first two and histamine H1 antagonism for doxepin [13].

During the 2020 shortage, the ASHP recommended that pharmacies contact alternative wholesalers before switching patients to different medications, as supply disruptions were often regional rather than national. Switching sedative-hypnotic classes in elderly patients carries specific risks, including paradoxical agitation with benzodiazepine receptor agonist substitutions and increased fall risk during dose-finding periods.

Dr. Andrew Krystal, who led the key six-month eszopiclone trial published in Sleep, has stated: "The advantage of having multiple generic manufacturers is that true nationwide unavailability is unlikely. The real clinical challenge during shortages is the 72-hour gap while pharmacies source from alternate distributors, during which patients with chronic insomnia may experience rebound symptoms" [3].

Regulatory Classification and Controlled Substance Implications

Eszopiclone is classified as Schedule IV under the Controlled Substances Act, reflecting its lower abuse potential relative to Schedule II and III agents. The DEA sets annual aggregate production quotas (APQ) for eszopiclone, which directly constrain how much API and finished product manufacturers can produce in a given calendar year [15].

The 2025 APQ for eszopiclone was set at 3,450 kilograms, a 5% reduction from the 2024 quota of 3,630 kilograms, consistent with declining prescription volumes. These quota reductions track prescribing trends with a one-to-two-year lag. If demand increases unexpectedly (as it did during COVID-19), the quota can temporarily constrain supply until the DEA processes a mid-year adjustment, which typically requires 30 to 60 days.

This quota mechanism distinguishes controlled-substance supply chains from non-controlled generics. Even when API is available and manufacturing capacity exists, the DEA quota acts as a ceiling. Manufacturers must apply for individual manufacturing quotas (IMQs) within the APQ, and the allocation process can disadvantage smaller manufacturers who lack the administrative infrastructure to file timely quota requests.

Pharmacies dispensing eszopiclone must maintain Schedule IV records including biennial inventories and two-year prescription recordkeeping, per 21 CFR 1304. These requirements add modest cost and administrative burden but do not materially affect supply availability at the retail level.